CD8A and neoplasm: As noted earlier, despite the initial focus on the role of tumor infiltrating CD8+ T cells in the response to checkpoint blockade, emerging data suggest that responses initiated outside of the tumor are a major contributor to the efficacy of therapy (11–13).